SS-31 potential benefits and areas of research

SS-31 is one of the few compounds in this catalog that stopped being purely investigational. Elamipretide holds FDA accelerated approval as Forzinity to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg (Forzinity prescribing information, DailyMed). In the larger and more general indication — primary mitochondrial myopathy — the pivotal phase 3 trial in 218 participants missed both of its co-primary endpoints (Karaa et al., Neurology, 2023; PMID 37268435).

That pairing is the most useful thing anyone can know about SS-31. It works well enough in one ultra-rare disorder to clear an accelerated-approval bar, and it did not improve walking distance or fatigue in the broader population of people who genuinely have mitochondrial disease.

Elamipretide belongs to the SS (Szeto-Schiller) series: small, cell-permeable, aromatic-cationic tetrapeptides that concentrate in the inner mitochondrial membrane and bind cardiolipin, the phospholipid that organises the electron transport chain's supercomplexes. A 2018 review in Protein and Peptide Letters by the series' inventor (PMID 30381054) summarises the preclinical case: in disease models these peptides improve electron-transport efficiency and ATP production, reduce reactive oxygen species, and limit downstream inflammation and tissue remodelling.

The distinguishing feature is targeting a subcellular structure rather than a cell-surface receptor. Most antioxidants scavenge radicals wherever they are; SS-31 is designed to sit in a specific membrane and stabilise its architecture. That review is written by the inventor and its evidence is animal and cellular — it explains why cardiolipin is a plausible target, and it is not a source for clinical effect sizes.

Barth syndrome is an X-linked TAFAZZIN disorder in which cardiolipin remodelling fails — mechanistically the closest possible match for a cardiolipin-binding drug, in a US population of roughly 150 people.

TAZPOWER ran a 28-week randomized, double-blind, placebo-controlled crossover phase followed by a 168-week open-label extension. Ten patients entered the extension on 40 mg subcutaneous elamipretide daily and eight reached week 168, with reported outcomes including a cumulative 96.1 m improvement on the six-minute walk test at week 168 (P=0.003), fatigue scores below baseline at all timepoints, and improvements in 3D left ventricular volumes (Thompson et al., Genetics in Medicine, 2024; PMID 38602181).

An eight-patient open-label extension with no placebo comparator is weak evidence by ordinary standards — which is precisely the trade-off accelerated approval exists to make in an ultra-rare disease. The label reflects it: approval was granted on improvement in knee extensor muscle strength as an intermediate clinical endpoint, with continued approval potentially contingent on confirmatory trials.

Elamipretide has a longer record of negative trials than positive ones, and they are informative rather than embarrassing:

• Primary mitochondrial myopathy (MMPOWER-3). 218 participants randomized to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks. It did not improve the six-minute walk test or total fatigue score — rated Class I evidence that it does not improve these outcomes at 24 weeks — while being well tolerated (PMID 37268435).
• Heart failure with reduced ejection fraction (PROGRESS-HF). 71 patients randomized to placebo, 4 mg, or 40 mg subcutaneously daily for 28 days. Elamipretide was well tolerated but did not improve left ventricular end-systolic volume at four weeks (PMID 32068002).
• Dry age-related macular degeneration (ReCLAIM). Phase 1 open-label studies of 40 mg subcutaneously daily for 24 weeks in high-risk drusen (n=21) and noncentral geographic atrophy (n=19) cohorts had safety and tolerability as their primary endpoint — adverse events were mild to moderate, predominantly injection-site reactions (PMID 36246187, PMID 36246181). Neither programme has produced an approval.

The pattern is consistent: a mechanistically targeted drug that helps most where the target defect is most specific, and does not generalise.

• MOTS-c — a mitochondrially encoded peptide acting as a metabolic signal via AMPK; SS-31 is a synthetic peptide that binds a membrane lipid. They share a compartment, not a mechanism.
• Humanin — another mitochondrial-derived peptide studied for cytoprotection, likewise a signalling molecule rather than a structural stabiliser.
• Conventional antioxidants — scavenge radicals broadly; SS-31's claim is architectural, stabilising cristae structure rather than mopping up.

• The approval is narrow: one ultra-rare genetic disease, a weight threshold, and a muscle-strength intermediate endpoint. It is not an endorsement for aging, fatigue, or general mitochondrial support.
• The largest well-controlled trial in people with genuine mitochondrial disease was negative — a strong argument against expecting benefit in healthy adults.
• Approved product is a specified 80 mg/mL sterile formulation with a label, renal dose adjustment, and known warnings. Research-grade "SS-31" is an unapproved product with none of those.